Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16422373 | 1.00 | MAOB (0.50) | MAOBMAOADPP4ALDH1A1CYP2D6 | |
| SCHEMBL1557855 | 0.81 | MAOB (0.41) | MAOBMAOAALDH1A1CYP2D6HSD11B1 | |
| SCHEMBL17985304 | 0.81 | MAOB (0.41) | MAOBMAOAALDH1A1CYP2D6HSD11B1 | |
| SCHEMBL16591486 | 0.81 | CCR2 (0.42) | MAOBMAOAALDH1A1CYP2D6HSD11B1 | |
| SCHEMBL4201312 | 0.78 | OPRM1 (0.46) | ALDH1A1CYP2D6HSD11B1 | |
| SCHEMBL19262093 | 0.77 | CCR2 (0.39) | MAOBMAOAALDH1A1CYP2D6HSD11B1 | |
| SCHEMBL1558872 | 0.75 | MAOB (0.36) | MAOBMAOAALDH1A1CYP2D6HSD11B1 | |
| SCHEMBL1019298 | 0.75 | ALDH1A1 (0.49) | ALDH1A1SLC6A3 | |
| SCHEMBL623955 | 0.75 | ALDH1A1 (0.46) | ALDH1A1CYP2D6HSD11B1SLC6A3 | |
| SCHEMBL19212422 | 0.73 | MAOB (0.39) | MAOBMAOAALDH1A1CYP2D6HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2832728-B1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL IND LTD (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2832728-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | MAOB 2922/4885MAOA 3398/4885DPP4 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.